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Abstract 
Review on PML, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: MYL, RNF71, TRIM19 
HGNC (Hugo): PML 
Location: 15q24.1 
 
Top: Courtesy Mariano Rocchi, Resources for Molecular 
Cytogenetics. Bottom: Metaphase FISH analysis of PML 
(green); red dots indicate centromere of chromosome 15 
(Subramaniyam et al., 2006). 
DNA/RNA 
Description 
PML is composed of 9 exons. Exons 7 and 8 can be 
divided into exons 7a, 7b, 8a and 8b. 
Transcription 
Transcription of PML generates 22 transcripts 
(splice variants) with at least 11 different isoforms 
(PMLI, PMLIa, PMLII, PMLIIa, PMLIII, PMLIV, 
PMLIVa, PMLV, PMLVI, PMLVIIa, PMLVIIb). 
Names of PML isoforms are based on the original 
nomenclature defined by Jensen et al., 2001. 
Pseudogene 
No pseudogenes have been reported so far. 
Protein 
Description 
Alternative splicing of PML gives rise to several 
isoforms with different molecular weight: PMLI is 
the longest isoform and is composed of 882 amino 
acids, while the shortest is PMLVIIb (435 amino 
acids).  
PML belongs to the family of the tripartite motif 
(TRIM).  
The RBCC/TRIM motif is present in all PML 
isoforms and is encoded by the exons 1-3. 
The RBCC domain is composed of a RING finger 
domain (R), two B-boxes domains (B1 and B2) and 
an α-helical coiled-coil domain (CC).  
The RING finger motif is a conserved cysteine-rich 
zinc-binding domain found in several classes of 
proteins. 
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Structural organization of PML human gene (Nisole et al., 2013). 
 
 
 
Schematic representation of PML isoforms (Nisole et al., 2013). 
 
 
The RING domain of PML is involved in the 
formation of the PML nuclear bodies (PML-NBs, 
see below) and in several others PML functions. 
Adjacent to the RING domain lay two cysteine-rich 
domains named B-boxes: these two domains have 
been proposed to work as second zinc-binding 
domain and they are involved in PML-NBs 
formation and in several others PML functions. The 
coiled-coil domain mediate PML homo- and hetero-
dimerization. The CC domain is also essential for 
PML-NBs formation and PML functions. A nuclear 
localization signal (NLS) is present in the isoforms 
but not in PMLVIIb. The SUMO interacting motif 
(SIM) of PML is required for the recognition and 
binding of SUMOylated proteins (Jensen et al., 
2001; Nisole et al., 2013). The SIM domain also 
contains the PML degron, involved in the CK2-
dependent PML degradation (Scaglioni et al., 
2006). PML undergoes several post-translational 
modifications. Several kinases phosphorylate PML 
on serine and threonine residues regulating its 
functions (Bernardi et al., 2004; Hayakawa and 
Privalsky, 2004; Scaglioni et al., 2006; Yang et al., 
2006). SUMOylation is the most intensely studied 
post-translational modification of PML. Both 
SUMO1 and SUMO2/SUMO3 bind covalently to 
PML. SUMOylation facilitates PML-NBs 
formation promoting tumor suppressive response 
PML-dependent, but also promotes leukemogenesis 
by the SUMOylation of PML-RARA. Finally, 
SUMOylation also promotes ubiquitin-mediate 
degradation of PML and PML-RARA (Fu et al., 
2005; Shen et al., 2006; Lallemand-Breitenbach et 
al., 2008; Kamitani et al., 1998a; Kamitani et al., 
1998b; Rabellino et al., 2012). Ubiquitination 
regulates PML functions and activity and 
deregulation of PML appears to be the common 
mechanism accounting for PML loss in tumors 
(reviewed in Rabellino and Scaglioni, 2013). 
Finally, PML can be also acetylated (Hayakawa et 
al., 2008). 
PML is the major constituent of the PML-NBs. 
PML-NBs are highly dynamic nuclear structures 
tightly bound to the nuclear matrix. Several 
functions of PML are related to the PML-NBs 
functions (reviewed in Bernardi et al., 2007). More 
than 150 different proteins have been shown to 
localize into PML-NBs (Van Damme et al., 2010). 
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Schematic representation of PML isoform IV protein domains. R = RING-finger domains, aa 55-91; B1, B2 = B-boxes 1 aa 124-
166 and 2 aa 184-228; CC = α-helical coiled-coil domain, aa 233-360; N = nuclear localization signal, aa 428-442; SIM = SUMO 
interacting motif, 508-518; D = degron. The three major SUMOylation sites (K60, K160 and K442) are indicated, as well as the 
major phosphorylation sites (T28, S36, S40, S480, T482, S517). 
 
Expression 
PML is ubiquitously expressed. 
Localisation 
Nuclear (PMLI-VI) and cytoplasmic (PMLVIIb). 
Function 
PML has been implicated in several cellular 
functions. 
Cellular senescence: PML is a key regulator of 
cellular senescence. PML is involved in oncogenic-
induced senescence (OIS) K-RAS dependent in a 
p53 dependent way (de Stanchina et al., 2004; 
Ferbeyre et al., 2000; Pearson et al., 2000; 
Scaglioni et al., 2012). PML is also involved in Rb-
dependent senescence (Mallette et al., 2004). 
Apoptosis: PML promotes apoptosis primarily by 
its ability to interact with p53 (Wang et al., 1998). 
Moreover, a pro-apoptotic function has been also 
attributed to the cytoplasmic isoform of PML 
(Giorgi et al., 2010). 
Neoangiogenesis: PML represses HIF1 
transcription, blocking de novo angiogenesis 
(Bernardi et al., 2006). 
Cell migration: PML is involved in the regulation 
of cell migration by the negatively regulating of β-1 
integrins (Reineke et al., 2010). 
DNA damage response: several proteins involved 
in DNA repair have been report to reside into PML-
NBs.  
Therefore, PML is also involved in DNA-repair, 
even though the mechanisms are still not 
completely clear (reviewed in Dellaire and Bazett-
Jones, 2004). 
Anti-viral response: several viral proteins interact 
with PML and the PML-NBs; moreover, several 
reports implicate PML and PML-NBs in anti-viral 
response (reviewed in Geoffroy and Chelbi-Alix, 
2011). 
Hematopoietic stem cell maintenance: PML has 
been reported being involved in hematopoietic stem 
cell maintenance by the regulation of the fatty acid 
oxidation (Ito et al., 2008; Ito et al., 2012). 
Several functions of PML are related to its ability to 
form PML-NBs.  
PML-NBs have been involved in tumor 
suppression, senescence and apoptosis, DNA-
damage response, cell migration, neoangiogenesis 
and anti-viral response (reviewed in Bernardi et al., 
2007). 
Homology 
PML is conserved in Amniota (source: 
HomoloGene). 
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Schematic representation of the mutations type of human PML found in human tumor samples (source COSMIC). 
 
Mutations 
Note 
PML-RARA is the product of the chromosomal 
translocation t(15;17) and it causes acute 
promyelocytic leukemia (APL) (de Thé et al., 1990; 
Goddard et al., 1991; Kakizuka et al., 1991; 
Pandolfi et al., 1991). 
Germinal 
No germinal mutations of PML have been reported. 
Somatic 
At least 65 different somatic mutations have been 
described. All the informations in this regard can be 
found at the COSMIC website. 
Implicated in 
Acute promyelocytic leukemia (APL) 
Note 
(de Thé et al., 1990; Goddard et al., 1991; Kakizuka 
et al., 1991; Pandolfi et al., 1991) 
Disease 
The balanced chromosomal translocation 
t(15;17)(q24;q21) causes APL by driving the 
synthesis of the PML-RARA oncoprotein. This 
translocation drives the production of three 
different PML-RARA variants, depending on the 
length of the PML module: a short variant PML(S)-
RARA, an intermediate variant PML(V)-RARA 
and a long variant PML(L)-RARA. Generally, 70% 
of the APL patients carry the PML(L)-RARA 
variant, followed by the PML(S)-RARA variant 
(20%) and the PML(V)-RARA (10%) (Melnick and 
Licht, 1999). PML staining in APL cells show a 
characteristic pattern commonly named 
"microspeckles" due to the fact that PML-RARA 
disrupts the PML-NBs. PML-RARA acts as a 
transcriptional repressor of RARA target genes. At 
the same time PML-RARA physically interacts 
with PML, impairing its tumor-suppressive 
functions. Combined, these features lead to the 
aberrant self-renewal of hematopoietic stem cells 
and block of differentiation of myeloid precursor 
cells at the promyelocytic stage (de Thé et al., 
2012). APL is a distinct subtype of acute myeloid 
leukemia (AML), is a rare condition though 
extremely aggressive and malignant.  
Clinically, APL symptoms tend to be similar to 
AML. APL is characterized by a severe 
coagulopathy, including disseminated intravascular 
coagulation (DIC). 
Prognosis 
APL is normally treated with the combination of 
retinoic acid (ATRA) and arsenic trioxide (ATO). 
This therapy leads to the remission of the disease in 
more than 90% of the cases. Notably, APL was the 
first malignant disease cured with targeted therapy 
(Lo-Coco et al., 2013). 
B-cell acute lymphoblastic leukemia 
(B-ALL) 
Note 
(Nebral et al., 2007; Qiu et al., 2011; Kurahashi et 
al., 2011) 
Disease 
The transcription factor PAX5 is required for 
development and maintenance of B-cell. Several 
chromosomal translocations involving PAX5 have 
been described, including the t(9;15)(p13;q24) in 
which the 5' region of PAX5 is fused to PML. So 
far, two cases of B-ALL PAX5-PML-dependent 
have been reported. The fused PAX5-PML 
oncoprotein has a dominant-negative effect on both 
PML and PAX5, inhibiting PAX5 activation of B-
cell specific genes and disrupting PML-NBs 
formation. 
Prognosis 
Kurahashi and colleagues suggest that B-ALL 
PAX5-PML dependent could be treated with ATO 
(Kurahashi et al., 2011). 
Various cancers 
Note 
Several reports indicate a reduced PML expression 
in several cancer types (Gurrieri et al., 2004; 
Rabellino et al., 2012; Rabellino and Scaglioni, 
2013). 
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Disease 
PML protein expression was reduced or abolished 
in prostate adenocarcinomas (63% [95% confidence 
interval {CI} = 48% to 78%] and 28% [95% CI = 
13% to 43%], respectively), colon adenocarcinomas 
(31% [95% CI = 22% to 40%] and 17% [95% CI = 
10% to 24%]), breast carcinomas (21% [95% CI = 
8% to 34%] and 31% [95% CI = 16% to 46%]), 
lung carcinomas (36% [95% CI = 15% to 57%] and 
21% [95% = 3% to 39%]), lymphomas (14% [95% 
CI = 10% to 18%] and 69% [95% CI = 63% to 
75%]), CNS tumors (24% [95% CI = 13% to 35%] 
and 49% [95% CI = 36% to 62%]), and germ cell 
tumors (36% [95% CI = 24% to 48%] and 48% 
[95% CI = 36% to 60%]) but not in thyroid or 
adrenal carcinomas (Gurrieri et al., 2004). In all the 
cases, PML mRNA levels are comparable to the 
healthy tissues and the PML gene is rarely mutated, 
but the protein levels of PML are reduced. This 
correlates with several reports that underline the 
role of PML degradation in tumor progression and 
maintenance (reviewed in Rabellino and Scaglioni, 
2013). 
Prognosis 
In most of the cases, loss of PML is associated with 
tumor progression, like was reported for prostate 
cancer, breast cancer and CNS tumors (Gurrieri et 
al., 2004). 
Breakpoints 
Note 
Breakpoint at q24, responsible of translocation 
t(15;17)(q24;q21). 
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